Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Twist Bioscience Corporation is a U.S.-based biotechnology company specializing in high-throughput, silicon-based DNA synthesis. The company operates within the synthetic biology, genomics, and biopharmaceutical research industries, providing synthetic DNA, genes, oligonucleotides, and related products that enable drug discovery, diagnostics, and biological research. Its core value proposition is the ability to produce DNA at scale with high accuracy and reduced cost compared to traditional synthesis methods.
Founded in 2013, Twist Bioscience developed a proprietary semiconductor-based manufacturing platform that miniaturizes DNA synthesis reactions onto silicon chips. This technology underpins the company’s competitive positioning, allowing it to serve academic institutions, biotechnology companies, pharmaceutical firms, and industrial customers. Over time, the company expanded from gene synthesis into next-generation sequencing (NGS) tools, antibody libraries, and DNA-based data storage, evolving into a diversified life sciences tools provider.
Business Operations
Twist Bioscience generates revenue primarily through the sale of synthetic DNA products, including Synthetic Genes, Oligo Pools, and NGS Tools, which represent its main operating segments. The company also offers Biopharma Solutions, such as antibody discovery libraries and optimization services, supporting therapeutic research and development. These business lines collectively serve research, clinical, and industrial applications.
Operations are supported by the company’s proprietary silicon-based DNA synthesis platform, which is manufactured at scale in its U.S. facilities. Twist conducts business globally, selling directly to customers and through strategic commercial partnerships. Notable operational relationships include collaborations with pharmaceutical companies and technology partners to co-develop antibody libraries and DNA-based technologies, while wholly owned subsidiaries support international sales and distribution.
Strategic Position & Investments
Twist Bioscience’s strategy centers on expanding its role as a foundational supplier to the synthetic biology ecosystem while driving adoption in higher-value biopharma and applied markets. Growth initiatives include increasing penetration in drug discovery workflows, expanding its antibody discovery and optimization offerings, and scaling production efficiency to improve margins. The company has also prioritized long-term innovation investments over near-term profitability.
A significant strategic investment area is DNA-based data storage, where Twist develops synthetic DNA as a medium for long-term digital information storage. The company has made targeted acquisitions to strengthen capabilities in antibody libraries and bioinformatics, integrating these assets into its core platform. While some emerging applications remain in early commercialization stages, Twist continues to allocate capital toward technologies aligned with large, long-term market opportunities.
Geographic Footprint
Twist Bioscience is headquartered in South San Francisco, California, with primary manufacturing and research operations located in the United States. The company maintains a global commercial presence, serving customers across North America, Europe, and Asia-Pacific through a combination of direct sales teams and regional subsidiaries.
International operations play a key role in revenue generation, particularly in European and Asian life sciences markets. Twist’s products are used by multinational pharmaceutical companies and research institutions worldwide, giving the company broad exposure to global biotechnology and genomics investment trends.
Leadership & Governance
Twist Bioscience was co-founded by Emily M. Leproust, who has played a central role in shaping the company’s technology-driven and innovation-focused culture. The leadership team emphasizes long-term platform development, scientific rigor, and scalable manufacturing as core elements of its strategic vision.
Key executives include:
- Emily M. Leproust – Chief Executive Officer and Co-Founder
- Patrick Finn – Chief Operating Officer
- Bill Banyai – Chief Financial Officer
- Paula Green – Senior Vice President, Biopharma Solutions
- Jim Thorburn – Senior Vice President, Commercial